MEDNAX Stock Forecast, Price & News

-0.57 (-1.95 %)
(As of 07/27/2021 10:48 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1,822 shs
Average Volume433,423 shs
Market Capitalization$2.47 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive MD News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDNAX and its competitors with MarketBeat's FREE daily newsletter.



MEDNAX, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. As of March 16, 2021, it operated a network of approximately 2,300 physicians. The company was founded in 1979 and is based in Sunrise, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.02 out of 5 stars

Medical Sector

1137th out of 2,218 stocks

Hospitals Industry

7th out of 10 stocks

Analyst Opinion: 0.9Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

MEDNAX (NYSE:MD) Frequently Asked Questions

Is MEDNAX a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEDNAX in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MEDNAX stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MD, but not buy additional shares or sell existing shares.
View analyst ratings for MEDNAX
or view top-rated stocks.

What stocks does MarketBeat like better than MEDNAX?

Wall Street analysts have given MEDNAX a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but MEDNAX wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is MEDNAX's next earnings date?

MEDNAX is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for MEDNAX

How can I listen to MEDNAX's earnings call?

MEDNAX will be holding an earnings conference call on Friday, August 6th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were MEDNAX's earnings last quarter?

MEDNAX, Inc. (NYSE:MD) issued its quarterly earnings data on Friday, May, 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.13 by $0.11. The business earned $446.80 million during the quarter, compared to the consensus estimate of $427.07 million. MEDNAX had a negative net margin of 41.46% and a positive trailing twelve-month return on equity of 10.90%. MEDNAX's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.32 EPS.
View MEDNAX's earnings history

How has MEDNAX's stock price been impacted by COVID-19 (Coronavirus)?

MEDNAX's stock was trading at $13.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MD shares have increased by 105.9% and is now trading at $28.80.
View which stocks have been most impacted by COVID-19

What price target have analysts set for MD?

5 brokerages have issued 12-month target prices for MEDNAX's shares. Their forecasts range from $14.00 to $30.00. On average, they anticipate MEDNAX's stock price to reach $23.83 in the next year. This suggests that the stock has a possible downside of 17.2%.
View analysts' price targets for MEDNAX
or view top-rated stocks among Wall Street analysts.

Who are MEDNAX's key executives?

MEDNAX's management team includes the following people:
  • Mr. Mark S. Ordan, CEO & Director (Age 62, Pay $1.44M)
  • Dr. Roger J. Medel, Co-Founder & Director (Age 74, Pay $1.45M)
  • Mr. C. Marc Richards, Exec. VP & CFO (Age 50, Pay $322.91k)
  • Mr. John C. Pepia, Sr. VP & Chief Accounting Officer (Age 58, Pay $799.4k)
  • Mr. Dominic J. Andreano, Exec. VP, Gen. Counsel & Sec. (Age 52, Pay $1.21M)
  • Dr. Roger Mack Hinson M.D., Pres of Pediatrix & Obstetrix Medical Groups (Age 57, Pay $1.24M)
  • Mr. Charles W. Lynch C.F.A., CFA, Sr. VP of Fin., Strategy & Investor Relations
  • Ms. Dana Dreher-Rodwell, VP & Chief Compliance Officer
  • Dr. James D. Swift M.D., Chief Devel. Officer
  • Ms. Claire M. Fair, Sr. VP & Chief HR Officer

What is Mark S. Ordan's approval rating as MEDNAX's CEO?

6 employees have rated MEDNAX CEO Mark S. Ordan on Glassdoor.com. Mark S. Ordan has an approval rating of 34% among MEDNAX's employees. This puts Mark S. Ordan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of MEDNAX's key competitors?

What other stocks do shareholders of MEDNAX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEDNAX investors own include NVIDIA (NVDA), AbbVie (ABBV), QUALCOMM (QCOM), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T), The Walt Disney (DIS), Wells Fargo & Company (WFC), Exxon Mobil (XOM) and Advanced Micro Devices (AMD).

What is MEDNAX's stock symbol?

MEDNAX trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."

Who are MEDNAX's major shareholders?

MEDNAX's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and Integrated Investment Consultants LLC (0.02%). Company insiders that own MEDNAX stock include Md Pascal J Goldschmidt, Michael Fernandez, Nicholas J Nikolopoulos and Roger Md Medel.
View institutional ownership trends for MEDNAX

Which institutional investors are buying MEDNAX stock?

MD stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Integrated Investment Consultants LLC.
View insider buying and selling activity for MEDNAX
or or view top insider-buying stocks.

How do I buy shares of MEDNAX?

Shares of MD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEDNAX's stock price today?

One share of MD stock can currently be purchased for approximately $28.80.

How much money does MEDNAX make?

MEDNAX has a market capitalization of $2.48 billion and generates $1.73 billion in revenue each year. The company earns $-796,490,000.00 in net income (profit) each year or $0.76 on an earnings per share basis.

How many employees does MEDNAX have?

MEDNAX employs 5,600 workers across the globe.

When was MEDNAX founded?

MEDNAX was founded in 1979.

What is MEDNAX's official website?

The official website for MEDNAX is www.mednax.com.

Where are MEDNAX's headquarters?

MEDNAX is headquartered at 1301 CONCORD TERRACE, SUNRISE FL, 33323.

How can I contact MEDNAX?

MEDNAX's mailing address is 1301 CONCORD TERRACE, SUNRISE FL, 33323. The company can be reached via phone at (954) 384-0175 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.